{"id":742167,"date":"2012-11-11T14:00:00","date_gmt":"2012-11-11T14:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/"},"modified":"2023-03-22T00:04:20","modified_gmt":"2023-03-22T04:04:20","slug":"merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/","title":{"rendered":"Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma"},"content":{"rendered":"<p class=\"bwalignc\">       Phase II Study Being Initiated     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of early interim results from a<br \/>\n      single-arm, open-label Phase IB study that has so far enrolled 132<br \/>\n      patients with advanced (inoperable and metastatic) melanoma who have<br \/>\n      received MK-3475, Merck\u2019s investigational immune-modulating<br \/>\n      therapy.&nbsp;Omid Hamid, M.D., Director of the Melanoma Center at the<br \/>\n      Angeles Clinic and Research Institute, Los Angeles, presented the data<br \/>\n      during a late-breaking clinical trials session at the Society for<br \/>\n      Melanoma Research of the 9th International Congress of the Society for<br \/>\n      Melanoma Research (SMR) in Hollywood, Calif.\n    <\/p>\n<p>\n      &#8220;A key element of Merck\u2019s oncology strategy is to identify therapeutic<br \/>\n      candidates with the potential to make a meaningful difference for<br \/>\n      patients with difficult-to-treat cancers,&#8221; said Gary Gilliland M.D.,<br \/>\n      Ph.D., senior vice president and oncology franchise head, Merck Research<br \/>\n      Laboratories. &#8220;Based upon the severe unmet medical need in advanced<br \/>\n      melanoma and the early interim results from this clinical trial, Merck<br \/>\n      is moving ahead with a clinical development program designed to analyze<br \/>\n      MK-3475 in a larger advanced melanoma population.&#8221;\n    <\/p>\n<p>\n      Patients were administered MK-3475 in one of three regimens: low dose<br \/>\n      every 3 weeks, high dose every 3 weeks and high dose every 2 weeks.<br \/>\n      Following an initial disease evaluation, patients received one of the<br \/>\n      three regimens of MK-3475. After 12 weeks, disease status was evaluated<br \/>\n      by the investigator and compared to baseline using immune-related<br \/>\n      response criteria (irRC). Those patients demonstrating stable disease or<br \/>\n      response at the 12-week evaluation time point continued to receive<br \/>\n      MK-3475 and follow-up monitoring.\n    <\/p>\n<p>\n      Data has so far been obtained for 85 of the 132 patients enrolled in the<br \/>\n      study. Of those patients, a total of 43 patients (51 percent) showed an<br \/>\n      objective anti-tumor response, and of those, 8 patients (9 percent)<br \/>\n      showed a complete response at or after the 12-week assessment. Notably,<br \/>\n      of the 27 patients who had previously been treated with ipilimumab<br \/>\n      monotherapy, the current standard of care for late-stage melanoma, 11<br \/>\n      patients (41 percent) showed an objective anti-tumor response to MK-3475<br \/>\n      monotherapy; none of those patients showed a complete response.\n    <\/p>\n<p>\n      The most common adverse events experienced by patients who received<br \/>\n      MK-3475 included fatigue, rash, diarrhea, nausea, cough, joint pain,<br \/>\n      fever and itching. Seven MK-3475 related Grade 3\/4 adverse events were<br \/>\n      reported as potentially \u201cimmune related.\u201d\n    <\/p>\n<p>\n      Merck recently initiated a global, randomized, Phase II clinical trial<br \/>\n      to evaluate MK-3475 versus standard chemotherapy for participants with<br \/>\n      advanced melanoma whose disease has progressed after prior therapy<br \/>\n      (reference: NCT01704287). Participants will be randomized to receive one<br \/>\n      of two doses of MK-3475 or investigator-choice chemotherapy. For further<br \/>\n      information, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=50473585&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.clinicaltrials.gov&amp;index=1&amp;md5=546c8d982c519b800c06c13e20eba5ed\">http:\/\/www.clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      <b>About PD-1 and MK-3475<\/b>\n    <\/p>\n<p>\n      Research has shown that PD-1, an immune checkpoint receptor, helps to<br \/>\n      confer immune resistance for some cancers allowing tumor cells to grow<br \/>\n      and proliferate unchecked.&nbsp;MK-3475 is a monoclonal antibody designed to<br \/>\n      target PD-1 to disrupt the role PD-1 plays in resisting the immune<br \/>\n      system.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50473585&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=8c443709116c198c199ab46d384dec70\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes &#8220;forward-looking statements&#8221; within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company&#8217;s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck&#8217;s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck&#8217;s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck&#8217;s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck&#8217;s 2011 Annual Report on Form 10-K and the company&#8217;s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC&#8217;s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50473585&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=47c011b9cc9ff45d518ecabd9894ae05\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ronald Rogers, 908-423-6449<br \/>or<br \/>Investors:<br \/>Carol        Ferguson, 908-423-4465<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phase II Study Being Initiated Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of early interim results from a single-arm, open-label Phase IB study that has so far enrolled 132 patients with advanced (inoperable and metastatic) melanoma who have received MK-3475, Merck\u2019s investigational immune-modulating therapy.&nbsp;Omid Hamid, M.D., Director of the Melanoma Center at the Angeles Clinic and Research Institute, Los Angeles, presented the data during a late-breaking clinical trials session at the Society for Melanoma Research of the 9th International Congress of the Society for Melanoma Research (SMR) in Hollywood, Calif. &#8220;A key element of Merck\u2019s oncology strategy is to identify therapeutic candidates with the potential to make a meaningful difference for patients with difficult-to-treat cancers,&#8221; said Gary Gilliland M.D., Ph.D., senior vice president and oncology franchise head, Merck Research Laboratories. &#8220;Based upon the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742167","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Phase II Study Being Initiated Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of early interim results from a single-arm, open-label Phase IB study that has so far enrolled 132 patients with advanced (inoperable and metastatic) melanoma who have received MK-3475, Merck\u2019s investigational immune-modulating therapy.&nbsp;Omid Hamid, M.D., Director of the Melanoma Center at the Angeles Clinic and Research Institute, Los Angeles, presented the data during a late-breaking clinical trials session at the Society for Melanoma Research of the 9th International Congress of the Society for Melanoma Research (SMR) in Hollywood, Calif. &quot;A key element of Merck\u2019s oncology strategy is to identify therapeutic candidates with the potential to make a meaningful difference for patients with difficult-to-treat cancers,&quot; said Gary Gilliland M.D., Ph.D., senior vice president and oncology franchise head, Merck Research Laboratories. &quot;Based upon the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\\\/\",\"name\":\"Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2012-11-11T14:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma - Merck.com","og_description":"Phase II Study Being Initiated Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of early interim results from a single-arm, open-label Phase IB study that has so far enrolled 132 patients with advanced (inoperable and metastatic) melanoma who have received MK-3475, Merck\u2019s investigational immune-modulating therapy.&nbsp;Omid Hamid, M.D., Director of the Melanoma Center at the Angeles Clinic and Research Institute, Los Angeles, presented the data during a late-breaking clinical trials session at the Society for Melanoma Research of the 9th International Congress of the Society for Melanoma Research (SMR) in Hollywood, Calif. \"A key element of Merck\u2019s oncology strategy is to identify therapeutic candidates with the potential to make a meaningful difference for patients with difficult-to-treat cancers,\" said Gary Gilliland M.D., Ph.D., senior vice president and oncology franchise head, Merck Research Laboratories. \"Based upon the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:20+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/","name":"Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2012-11-11T14:00:00+00:00","dateModified":"2023-03-22T04:04:20+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121111005025r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-early-stage-interim-data-for-mk-3475-an-investigational-therapy-for-the-treatment-of-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"bdf670c2-704c-44ee-9ab1-7d0a098df1fc","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Presents-Early-Stage-Interim-Data-for-MK-3475-an-Investigational-Therapy-for-the-Treatment-of-Advanced-Melanoma-2012.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742167\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742167"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}